Genmab — November 2016
-
Offentliggjorde indsendelse af registreringsansøgning i USA og Europa for daratumumab til behandling af recidiverende eller refraktær myelomatose, hvilket udløste milestoneindtægter på USD 25 mio.
De amerikanske sundhedsmyndigheder (FDA) tildelte for anden gang Breakthrough Therapy Designation-status til daratumumab
Offentliggjorde, at FDA har godkendt Arzerra
(ofatumumab) i kombination med fludarabin og cyclofosfamid til behandling af recidiverende kronisk lymfatisk leukæmi (CLL)
Indgik kommer -
372 mio salg darzalex
-
Det er nu en pæn opjustering.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind